NRIX
Nurix Therapeutics, Inc.
Next earnings Jul 7, 2026 · consensus $-0.72 EPS, $18.0M rev
Last earnings -4.6% on 2026-04-08
$19.30
▲ +2.33%$19.30▲ +69.45%
over 1Y
L $8.24EODHDH $21.47
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.3%
1W+12.7%
1M+11.0%
3M+25.0%
YTD+6.9%
1Y+69.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 23 analysts
Strong Buy
Revenue grew 54.0% YoY; but unprofitable (net margin -314.9%).
Nurix Therapeutics, Inc. shows $84.0M in FY2025 revenue (+54.0% YoY), a -314.9% net margin, and -49.1% ROE.
Sources: SEC EDGAR (CIK 0001549595, latest 10-Q filed 2026-04-08) · EODHD · as of 6/24/2026, 11:03:40 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.